BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 40,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health.
BD Life Sciences
This plant manufactures a broad range of blood collection products and systems including BD Vacutainer® tubes for haematology, coagulation and special chemistries, and supplies markets both across Europe and around the world. The Plymouth facility, which employs approximately 720 associates, also manufactures BD Biosciences - Discovery Labware products which are used by medical researchers.
This facility is home to approximately 230 sales, marketing and technical support staff from the Company's three segments: BD Medical, BD Diagnostics and BD Biosciences. The Oxford office is also the European headquarters for two of the largest units (BD Diagnostics - Preanalytical Systems and BD Medical - Medical Surgical Systems). These units are supported by a team of experts from the human resources, information technology, customer service, procurement and finance departments.
This facility employs approximately 200 associates and specialises in the development and manufacture of plastic purpose-designed drug delivery systems which are supplied to the pharmaceutical industry for filling and distribution to end users worldwide.
In April 2006, BD approved a €15 million investment to develop and expand its medical devices global manufacturing center in Drogheda. The investment prepared the Drogheda facility to manufacture a high-value prefilled syringe known as the BDTM Saline XS. The expansion has been built with capacity for a second line to cater to the rapidly growing European market.
Beginning in 1969, the Dun Laoghaire facility manufactured a variety of syringes until 1996, when the site began diversifying into pen needles, an insulin injection system for the treatment of diabetes. In January 2007, the last 0.5ml syringe was manufactured. As of April 2007, the Dun Laoghaire facility has 11 operating pen needle lines.
1 Becton Drive
Franklin Lakes, NJ USA 07417
Becton, Dickinson U.K. Limited
Registered in England: 00852702
Registered Office: The Danby Building, Edmund Halley Road, Oxford Science Park, Oxford
Oxfordshire OX4 4DQ